full image - Repost: 4DX PARTNERS WITH STANFORD AND EXPANDS TO BRAZIL! *HUGE NEWS** (from Reddit.com, 4DX PARTNERS WITH STANFORD AND EXPANDS TO BRAZIL! *HUGE NEWS**)
Mining:
Exchanges:
Donations:
FINALLY SOME GOOD NEWS!!https://ift.tt/JKjOlyG put my trust and faith into 4D Medical i knew they were cooking something huge. From now its just operating and a straight journey to the moon hopefully. more info on the doc can be found from a direct annoucement release from 4DX. But if you guys dont have access to that lemme know and ill summarize it for you. Some key things people can keep in mind though mentioned in the annoucement:"Stanford's commercial deployment marks the beginning of 4DMedical's planned rollout strategy across a network of Key Opinion Leader (KOL) sites at leading U.S. AMCs.""Building on the initial rollout at Hospital Madre Teresa in Belo Horizonte, 4DMedical and AstraZeneca are rapidly expanding their Lung Health Screening Program across Brazil with the addition of five new hospitals, representing an annual volume of approximately 38,000 additional CT scans."AND my fav ceo Andreas Fouras says"Our partnership with AstraZeneca continues to gain exceptional momentum. The expansion of the Brazilian Lung Health Screening Program to five additional hospitals, within just weeks of launch, demonstrates both the scalability of our platform and its growing importance in large-scale population health initiatives. Stanford's transition to a full commercial CT:VQ™ contract, less than two months after FDA clearance, represents a powerful validation of our go-to-market strategy. As a globally respected leader in clinical innovation and lung imaging, Stanford serves as an ideal anchor for our CT:VQ™ commercialisation approach: establishing a network of opinion leading sites across key U.S. AMCs to accelerate awareness, adoption, and confidence in CT:VQ™ as the new standard of care in pulmonary imaging. We are immensely proud to have Stanford as the first AMC to implement CT:VQ™ following FDA clearance. The momentum we are experiencing demonstrates the interest and excitement in CT:VQ™ from healthcare providers, creating a fundamental shift in our trajectory post-FDA clearance. We are on track for an extremely strong FY26, and I look forward to sharing further progress with shareholders ahead of RSNA in November."
Social Media Icons